JP Morgan Chase & Co.

JP Morgan Initiates coverage on Imperva (NYSE: IMPV) with an Outperform rating and $31 per share JP Morgan says, "Security attacks up until 2007 focused on the network (layer 3), but attackers are now focusing on the more valuable data within a company. This has created an opportunity to...

JP Morgan reiterates its Overweight rating on Darden Restaurants (NYSE: DRI) and lowers its price target to $51 from $53 per share as earnings visibility remains low. JP Morgan notes, "DRI reported F2Q12 (Nov) EPS of $0.41 (-24% y/y) as preannounced on December 6th. Versus our estimate, lower...

JP Morgan reiterates its Overweight rating on Honeywell (NYSE: HON) and raises its price target to $56 from $55 per share as it 2012 sees a good start following disappointing Q4 update. JP Morgan comments, "While the 4Q update was disappointing, initial 2012 guidance shows Honeywell on track...

JP Morgan reiterates its Overweight rating on Zebra Technologies (NASDAQ: ZBRA) as it reflects potential slowdown due to EMEA sovereign debt challenges. JP Morgan says, "Subsequent to the financial crisis of 2008, ZBRA experienced several quarters of severe y/y revenue decline. Though...

JP Morgan initiates coverage on Zeltiq Aesthetics (NASDAQ: ZLTQ) with an Overweight rating and a price target of $16 per share to reflect its large market opportunity with minimal regulatory risk. JP Morgan comments, "We estimate there to be an addressable market in the tens of millions of...

As a German official questioned a second Greek bailout on Monday, the EUR/USD slips but still holds near its 1-month high. This week, the European Central Bank (ECB) will release its policy decision, which is likely to have a heavy influence on EUR/USD. The euro steepened its decline after Jean-...

According to Citi, JP Morgan Chase & Co (NYSE: JPM) reported 1Q11 EPS of $1.28 vs its $1.33 estimate and consensus of $1.16. Citi reported that core PTPP of $11.6 billion came in ~$400 million better than its expectations driven by strong performance in the I-Bank, offset by modest weakness...

J.P. Morgan is out with a research report this morning, where it reiterated its Overweight rating on shares of Apollo Group (NASDAQ: APOL); it has an $85.00 price target on the stock. The JPM analysts said, “Yesterday after the close, Apollo reported a solid 3QF10 (May) EPS of $1.74, above our...

J.P. Morgan is out with an analyst note this morning, where they reiterated their Neutral rating on shares of Atheros Communications (NASDAQ: ATHR); they have a $47.00 price target on the stock. JPM analysts said that their “checks indicate that 2Q is tracking to plan (revenues up 9.5% Q/Q at mid...

Shares of Mindray Medical (NYSE: MR) are on the rise this morning by 1.90% to $32.79 after J.P. Morgan (NYSE: JPM) raised the price target for the stock to $43. MR is now rated “overweight.” JPM Analysts said that MR’s Q1 2010 results showed “remarkable recovery in exports and flat domestic sales,...

Shares of Mindray Medical (NYSE: MR) are on the rise this morning by 1.90% to $32.79 after J.P. Morgan (NYSE: JPM) raised the price target for the stock to $43. MR is now rated “overweight.” JPM Analysts said that MR’s Q1 2010 results showed “remarkable recovery in exports and flat domestic sales,...

Oppenheimer analysts Chris Kotowski, Benjamin Chittenden, and Kaimon Chung reiterated their Outperform rating for shares of JP Morgan Chase & Co. (NYSE: JPM) with a price target of $54. The analysts believed that JP Morgan Chase & Co. "has a well-positioned and well-managed portfolio of...